The effects of anabolic androgenic steroids on serum ubiquinone and dolichol levels among steroid abusers.
We measured serum ubiquinone and dolichol concentrations in 13 men while they abused anabolic androgenic steroids (AAS) and during the following withdrawal period. Serum total, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) cholesterol and triglycerides were also determined. AAS administration increased serum ubiquinone by 68% (P < .001) and decreased serum dolichol by 30% (P < .002). Both nonsterol isoprenoid levels in plasma correlated with the AAS dose, ubiquinone positively (P < .001) and dolichol negatively (P < .002). When the subjects were taking steroids, the ubiquinone to LDL ratio was 42% higher than during the withdrawal period. In conclusion, our study suggests that AAS have an influence on the by-products of the mevalonate pathway.
Karila
T
T
National Public Health Institute, Laboratory of Pharmacology and Toxicology, Helsinki, Finland.
Laaksonen
R
R
Jokelainen
K
K
Himberg
J J
JJ
Seppälä
T
T
D000328:Adult; D045930:Anabolic Agents / Q000009:adverse effects*; D001161:Arteriosclerosis / Q000209:etiology; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004286:Dolichols / Q000097:blood*; D006801:Humans; D008297:Male; D008798:Mevalonic Acid / Q000378:metabolism; D019966:Substance-Related Disorders / Q000097:blood / Q000150:complications; D014451:Ubiquinone / Q000097:blood*
D045930:Anabolic Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004286:Dolichols; D014451:Ubiquinone; D008798:Mevalonic Acid